WuXi XDC Research Platform & Capability for Integrated Bioconjugation Discovery Services

WuXi XDC
Since the year of 2000, there’re 13 ADCs on the market and 9 of them were approved in the last three years. The enthusiasm of pharmaceutical and biotechnology companies for the research and development of ADC has been increasing.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Contamination control strategies: How to achieve faster, easier process monitoring

A contamination control strategy (CCS) considers microbiological monitoring of assessed points and is a fundamental aspect of managing risks associated with contamination.
Watch Now

Magnetic 3D Bioprinting of Cells: Overcoming Imaging Obstacles in Spheroids

GE Bio Research

Interest in 3D cell culture has grown exponentially in recent years, partially due to 3D cultures helping to overcome the challenges of using animal models and inadequacy of 2D cultures. Challenges are still present because of the physical nature of 3D cultures, especially when using confocal microscopy for visualization as a result of limited light penetration through 3D structures. To overcome these limitations, Nano3D Biosciences and MD Anderson together have developed methods and protocols using magnetic 3D bioprinting techniques to successfully overcome such challenges. The results have helped to identify novel approaches to study biology using 3D cell culture and automated confocal imaging of spheroids.
Watch Now

AMS - 2021-EMde-Emergency Medicine- Dermatology

americanmedicalseminars.com

EMde-Emergency Medicine- Dermatology: Drug Eruptions: Etiology, Differential Diagnosis and Treatment; Cutaneous Infections and Infestations, Part I: Bacterial, Viral, and Fungal; Cutaneous Infections and Infestations, Part II: Parasites, Bites, and Stings.
Watch Now

High Throughput, Low Volume Subvisible Particle Analysis

Halo Labs

Subvisible particle analysis is a key predictor of protein drug stability and a key formulation, quality metric. However, current methods use large volumes of precious protein solutions and are labor- and time-intensive, making this data inaccessible during late-stage candidate screening or early in formulation. Moreover, regulatory agencies are tightly enforcing subvisible particle content in biopharma formulations at unprecedented levels, making early detection of subvisible particles, like protein aggregates, a key analytical priority.
Watch Now

Spotlight

resources